All News

RheumNow Podcast square

RheumNow Podcast – Great Associations (3.19.2021)

Jack Cush, MD

Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.

Read Article
URI.infection.COrona.jpg

Rheumatic Patients Are at Risk for COVID Death

MedPage Today

Patients with rheumatic diseases who developed COVID-19 were at increased likelihood of death, with risk factors similar to those seen in the general population but also because of factors specific to their underlying disease and its treatment, analysis of data from an international registry foun

Read Article
RheumNow Podcast square

RheumNow Podcast – Listener Questions (3.12.2021)

Jack Cush, MD

Dr Jack Cush reviews the news, Journal reports, CDC guidelines and viewer questions from the last week on RheumNow.com

Read Article
Vaccine2.jpg (keep)

Low Anaphylaxis Risk with COVID mRNA Vaccines

Jack Cush, MD

JAMA reports a safety survey of hospital employees showing that the risk of anaphylaxis from mRNA vaccines is 2.47 per 10,000 individuals. 

Read Article
COVID.virus_.corona.jpg (keep)

COVID-19-Related Deaths in Rheumatic Disease Patients

Jack Cush, MD

There is a growing body of evidence regarding COVID-19 outcomes (including death) in rheumatic disease patients; analysis of a German registry shows that poor control, rituximab, sulfasalazine and other immunosuppressives could be risk factors for COVID-related death.

Read Article
COVID vaccine vials

Comparison of Three Coronavirus Vaccines

Jack Cush, MD

On Feb. 27, the Food and Drug Administration announced it has issued an emergency use authorization for Johnson & Johnson’s one-dose Covid vaccine, making it the third COVID-19 vaccine to be commercially available.  We've compiled a comparison table and some key information relevant to your delivering patient guidance henceforth. 

Read Article
vaccination.jpg

CDC: Interim Guidance for COVID Vaccinated People

Jack Cush, MD

Among 330 million Americans, roughly 32.1 million have been fully vaccinated and 61.1 million have received at least one dose of a COVID-19 vaccine (as of March 8th).

Read Article
Survey of 500 pts with systemic rheumatic diseases during the COVID-19 pandemic showed few who discontinuations Rx - 2.2% D/C for fear of immunosuppression; 3.8% for shortages (mostly HCQ); 2.6%) for resp infx and 6% for side-effects. https://t.co/2BJIYeBSIu

Links:

Dr. John Cush RheumNow ( View Tweet)

Hydroxychloroquine studied vs Vitamin C (PBO) prophylaxis to households (n=671) exposed to COVID-19. 89% were COVD1-9 test neg at baseline. HCQ did not protect against progression to COVID (53 vs 45 events; adj HR, 1.10 [95% CI, 0.73 to 1.66]. A vit C Win! https://t.co/S5qjdIYaXq

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Comparison of Three Coronavirus Vaccines https://t.co/omxsA8W3nQ https://t.co/s7dc9NwMQo

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Rheumatic Patients Are at Risk for COVID Death https://t.co/bhJG1vuVA4 https://t.co/VEN3nwSOPB

Links:

Dr. John Cush RheumNow ( View Tweet)
REMDACTA trial of Actemra plus remdesivir failed to meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia (nor its key secondary endpoints) compared to remdesivir alone https://t.co/OyqpnwUVXU

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Low Anaphylaxis Risk with COVID mRNA Vaccines JAMA reports a safety survey of hospital employees showing that the risk of anaphylaxis from mRNA vaccines is 2.47 per 10,000 individuals. https://t.co/hN7UWNasQo https://t.co/0UhOZuGze1

Links:

Dr. John Cush RheumNow ( View Tweet)
COVID Vaccine Rebuttals by Dr. Kathryn Dao ( @KDAO2011) Dr. Dao addresses the common vaccine concerns that have been posed to her and her rebuttals. https://t.co/f5gwBICEGy https://t.co/Nzm1HfY5GW

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Low Anaphylaxis Risk with COVID mRNA Vaccines JAMA reports a safety survey of hospital employees showing that the risk of anaphylaxis from mRNA vaccines is 2.47 per 10,000 individuals. https://t.co/hN7UWNasQo https://t.co/pVlaTUSCH7

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: COVID-19-Related Deaths in Rheumatic Disease Patients There is a growing body of evidence regarding COVID-19 outcomes (including death) in rheumatic disease patients... https://t.co/N3SGTnTjsq https://t.co/Xlnt3oxKbo

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: CDC: Interim Guidance for COVID Vaccinated People https://t.co/3GZDCVF0hv https://t.co/qyQyajjqM8

Links:

Dr. John Cush RheumNow ( View Tweet)
Data Safety committee has closed recruitment to the colchicine arm in the RECOVERY trial a UK study of outcomes in COVID-19. Among 11162 enrolled pts (2178 deaths) those Rx w/ Colchicine had same 28 day mortality as usual care (20% vs. 19%) https://t.co/8gUc8LAZTp

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Baricitinib Therapy in Covid-19 Pneumonia https://t.co/b3tsLcoXay https://t.co/tjqkk1RLFZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Influenza Numbers are way down this year due to COVID mitigation methods, school/office closings, reduced travel/mobility. As of Jan 31st only 155 hospitalized with the flu (98% less than 2019-2020 flu season - 8,633 people were hospitalized with the flu) https://t.co/6c2YQKbt57?

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×